| Literature DB >> 21621998 |
Austin Chen1, Louis-Charles Campeau, Elizabeth Cauchon, Amandine Chefson, Yves Ducharme, Daniel Dubé, Jean-Pierre Falgueyret, Pierre-André Fournier, Sébastien Gagné, Erich Grimm, Yongxin Han, Robert Houle, Jing-Qi Huang, Patrick Lacombe, Sébastien Laliberté, Jean-François Lévesque, Susana Liu, Dwight MacDonald, Bruce Mackay, Dan McKay, M David Percival, Chris Regan, Hillary Regan, René St-Jacques, Sylvie Toulmond.
Abstract
An SAR campaign aimed at decreasing the overall lipophilicity of renin inhibitors such as 1 is described herein. It was found that replacement of the northern appendage in 1 with an N-methyl pyridone and subsequent re-optimization of the benzyl amide handle afforded compounds with in vitro and in vivo profiles suitable for further profiling. An unexpected CV toxicity in dogs observed with compound 20 led to the employment of a time and resource sparing rodent model for in vivo screening of key compounds. This culminated in the identification of compound 31 as an optimized renin inhibitor.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21621998 DOI: 10.1016/j.bmcl.2011.05.013
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823